Detailed Information on Publication Record
2005
Mitoxantrone therapy in rapidly worsening multiple sclerosis
BENEŠOVÁ, Yvonne, Pavel ŠTOURAČ, M. BERÁNEK and Zdeněk KADAŇKABasic information
Original name
Mitoxantrone therapy in rapidly worsening multiple sclerosis
Name in Czech
Léčba mitoxantronem u rychle progredující roztroušené sklerózy
Authors
BENEŠOVÁ, Yvonne (203 Czech Republic), Pavel ŠTOURAČ (203 Czech Republic, guarantor), M. BERÁNEK (203 Czech Republic) and Zdeněk KADAŇKA (203 Czech Republic)
Edition
Bratislavské lekárske listy, Bratislava, LF UK, 2005, 0006-9248
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30000 3. Medical and Health Sciences
Country of publisher
Slovakia
Confidentiality degree
není předmětem státního či obchodního tajemství
RIV identification code
RIV/00216224:14110/05:00014829
Organization unit
Faculty of Medicine
Keywords in English
multiple sclerosis; immunotherapy; mitoxantrone; EDSS
Tags
Reviewed
Změněno: 7/12/2006 20:45, prof. MUDr. Josef Bednařík, CSc.
V originále
The aim of the study was to asses the effect and safety of mitoxantrone (MX) therapy in patients with relapsing remitting and secondary progressive multiple sclerosis (MS). Thirty-three patients (10 males, 23 females, mean age 48.5+/-9.9 years) with relapsing remitting and secondary progressive MS were followed. The disability was evaluated using Expanded Disability Status Scale (EDSS). The mean time period from the onset to secondary progressive course of the disease was 9.3+/-9.8 years. Patients, whose disability progression increased by one or more EDSS points per one year, and who did not respond to other therapy, were treated with mitoxantrone. Patients were treated monthly with intravenous administration of mitoxantrone 12 mg/m2 (not exceeding the maximum cumulative dose of 140 mg/m2) and methylprednisolone 1000 mg. Six pulses were administered in each patient. EDSS score was measured at the beginning of the treatment and after twelve months. Disability progression was evaluated. Nonparametric Wilcoxon matched pair test was used for statistical analysis.
In Czech
Cílem studie bylo zhodnotit efekt a bezpečnost léčby mitoxantronem (MX) u nemocných s relabující a sekundárně progresivní roztroušenou sklerózou (RS). Bylo sledováno 33 pacientů (10 mužů, 23 žen, o průměrném věku 48,5+/- 9,9 let), neschopnost byla hodnocena pomocí Expanded Disability Status Scale (EDSS). Léčba mitoxantronem byla zavedena u nemocných, u kterých došlo během jednoho roku ke zhoršení EDSS skóre o minimálně 1 bod a nereagovali na jinou léčbu. Pacienti byli léčeni 6 pulsy mitoxantronem intravenózně každý měsíc v dávce 12 mg/m2, (celková kumulativní dávka nepřekročila 140 mg/m2) a metylprednisolonem v dávce 1000 mg. Byla zhodnocena progrese EDSS v průběhu 1 roku.
Links
| MSM0021622404, plan (intention) |
|